Biotech Investing: Sunny Side of Street? Dark Side of Moon?
BioWorld Insight Contributing Writer
Generous valuations, early stage programs drawing VC attention, start-ups undaunted by an inhibiting economy, big pharma's bio-fixation, M&A activity's robust start and an FDA on a roll of approvals are some of the dynamics that have most – but not all – investors seeing the biotech market as a relative five-years-out investment haven, according to a panel at the BIO CEO & Investor Conference and also the results of a new BIO survey.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter